title: Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome.
abstract: OBJECTIVE
  To determine if the somatostatin analog, octreotide, affects insulin and related peptides and, hence, androgen levels differently between polycystic ovary syndrome (PCOS) patients and controls.
  
  
  METHODS
  Prospective controlled trial.
  
  
  METHODS
  Reproductive endocrinology clinic of our medical center.
  
  
  METHODS
  Eleven women with PCOS and six matched ovulatory controls.
  
  
  METHODS
  Octreotide (100 micrograms) was administered subcutaneously in the midfollicular phase. Serum was obtained before and at 60, 120, 180, and 240 minutes after octreotide.
  
  
  METHODS
  Fasting insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), T, androstenedione (A), and LH.
  
  
  RESULTS
  In PCOS, baseline levels of T, A, LH, and fasting insulin were significantly higher than in controls. Pretreatment IGF-1 and IGFBP-3 levels were similar in PCOS and controls. Octreotide reduced fasting insulin levels significantly but to a similar degree in control and PCOS patients (77% and 90%, respectively). Both groups also experienced a significant decrease in LH levels after octreotide administration, but no significant changes were demonstrated in serum T or A. However, serum IGF-1 suppression in PCOS was greater (63% versus 8% in controls). Serum IGFBP-3 levels increased after octreotide administration in both groups with a larger increase (40%) occurring in the PCOS patients.
  
  
  CONCLUSIONS
  These data suggest that women with PCOS may be more sensitive to the effects of octreotide in decreasing IGF-1 and increasing IGFBP-3. Although no significant changes could be demonstrated in ovarian androgens after a single dose, octreotide effectively reduced serum LH and insulin and, as such, may prove useful in treating some patients with PCOS.
authors.affiliation: University of Southern California, Los Angeles.
authors.forename: R S
authors.initials: RS
authors.lastname: Morris
authors.forename: E
authors.initials: E
authors.lastname: Carmina
authors.forename: M A
authors.initials: MA
authors.lastname: Vijod
authors.forename: F Z
authors.initials: FZ
authors.lastname: Stanczyk
authors.forename: R A
authors.initials: RA
authors.lastname: Lobo
mesh_terms: D000293:Adolescent; D000328:Adult; D000735:Androstenedione / Q000097:blood; D002352:Carrier Proteins / Q000097:blood*; D005215:Fasting; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000097:blood; D015282:Octreotide / Q000494:pharmacology*; D011085:Polycystic Ovary Syndrome / Q000097:blood*; D011446:Prospective Studies; D013739:Testosterone / Q000097:blood
chemical_list: D002352:Carrier Proteins; D007328:Insulin; D018969:Insulin-Like Growth Factor Binding Proteins; D013739:Testosterone; D000735:Androstenedione; D007334:Insulin-Like Growth Factor I; D007986:Luteinizing Hormone; D015282:Octreotide